People · Operator
Named in public records as an officer, director or promoter · active 2008–2016 · Biotechnology, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Intarcia Therapeutics, Inc | — | Biotechnology | Growth/Late | $1.2B | $8.4B | 2012 |
| Eiger Biopharmaceuticals Inc | — | Biotechnology | Series A | $70.9M | $216.9M | 2008 |
| Altheos, Inc. | — | Other | Series B | $23.1M | $275.1M | 2011 |
| Acucela Inc | — | Biotechnology | Pre-Seed | $440K | $24.3M | 2009 |
Glen Sato at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Glen Sato on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Michael Williams | 1 | 27 |
| Bryan Roberts | 1 | 18 |
| Wende Hutton | 1 | 16 |
| Ed Mathers | 1 | 11 |
| Nina Kjellson | 1 | 11 |
| Peter Bisgaard | 1 | 9 |
| Rob Hopfner | 1 | 6 |
| PATRICK CONWAY | 1 | 6 |
| Gino Santini | 1 | 5 |
| Kurt Graves | 1 | 5 |
| Thomas Dietz | 1 | 4 |
| Jay Skyler | 1 | 3 |
| Paul Truex | 1 | 3 |
| Jay Smith | 1 | 2 |
| Wenjin Yang | 1 | 2 |
| James Ahlers | 1 | 2 |
| James Niedel | 1 | 2 |
| David Franklin | 1 | 2 |
| Jeffrey Glenn | 1 | 2 |
| Bryan L. Roberts | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.